| نویسنده | نفر چندم مقاله |
|---|---|
| زهرا شیخ علیپور | اول |
| لیلا واحدی | دوم |
| فرزاد کاکائی | سوم |
| پروین رحمانی | چهارم |
| فاطمه ملائی توانی | پنجم |
| امید زادی آخوله | ششم |
| طاهر استبصاری | هفتم |
| عنوان | متن |
|---|---|
| خلاصه مقاله | Abstract Background: Knowledge on SARS-CoV-2 infection in liver transplant recipients is insufficient, particularly in terms of severity of the disease and immunosuppressive therapy. The aim of this study was to describe the demographic, clinical characteristics, immunosuppressive therapy and the outcomes of liver transplant recipients with COVID-19. Methods: A retrospective study was conducted across Northwest of Iran on liver transplant recipients with SARS-CoV-2 infection during the first and second outbreak of COVID-19 pandemic in Iran. Baseline characteristics, clinical presentation, management of immunosuppressive therapy and outcomes were collected. Results: 7 patients were included (99% male, median (IQR) age at diagnosis 64 (44-74) years). Two patients had arterial hypertension and one had ulcerative colitis. The most common symptoms were cough, hoarseness and nasal congestion. Immunosuppression was continued in all of the patients. 6 patients were hospitalised and one was cared at home. Overall, 5 patient recovered from the COVID-19 and 2 patients died. One of the seven patients who died had a history of cancer. Conclusion: According to the results of this study all of the liver transplant recipients with SARS-CoV-2 infection received immunosuppression as before infection. It seems that it did not increased the fatality rate any more. Therefore it is necessary to do more studies to see if the immunosuppression should be discontinued or continued after infection. |
| کلمات کلیدی | Keywords: COVID-19; Liver Transplant Recipients; Immunosuppressant |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| covid_4546641.doc | 1402/03/17 | 114688 | دانلود |
| Govahi.pdf | 1402/03/17 | 1038536 | دانلود |